Work

Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.tps8585

Authors: Helen J. Ross, David E. Kozono, James John Urbanic, Terence Marques Williams, Carter Dufrane, Ilze Bara, Mayank Gandhi, Katja Schulze, Jane Michelle Brockman, Xiaofei F. Wang, Everett E. Vokes, Tom Stinchcombe

Institutions: Mayo Clinic in Arizona, Dana-Farber Cancer Institute, University of California San Diego, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Alliance Foundation Trials, Genentech, Duke Medical Center, University of Chicago, University of Chicago Medical Center, University of North Carolina at Chapel Hill

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891576167

Cites:

Cited by: 6

Related to: 10